Standards of care for treatment of recurrent glioblastoma--are we there yet?
about
Oncolytic viruses as immunotherapy: progress and remaining challengesThe evolving roles and controversies of radiotherapy in the treatment of glioblastomaNonsurgical treatment of recurrent glioblastomaConsensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trialsIDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in gliomaHarnessing immunosurveillance: current developments and future directions in cancer immunotherapyAfatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.External beam re-irradiation, combination chemoradiotherapy, and particle therapy for the treatment of recurrent glioblastomaHERG K+ channel-dependent apoptosis and cell cycle arrest in human glioblastoma cellsComprehensive analysis of glycolytic enzymes as therapeutic targets in the treatment of glioblastomaOvercoming therapeutic resistance in glioblastoma: the way forwardPrediction of tumor recurrence and therapy monitoring using ultrasound-guided photoacoustic imaging.Long-term survival (>13 years) in a child with recurrent diffuse pontine gliosarcoma: a case report.Antiangiogenic therapy of brain tumors: the role of bevacizumab.Pros and cons of current brain tumor imagingDiffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma.Survival following reirradiation using intensity-modulated radiation therapy with temozolomide in selected patients with recurrent high grade gliomasIntegrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma.Progression pattern and adverse events with bevacizumab in glioblastoma.Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.Glioma cancer stem cells secrete Gremlin1 to promote their maintenance within the tumor hierarchy.Expression of Cathepsins B, D, and G in Isocitrate Dehydrogenase-Wildtype Glioblastoma.Phosphatidylserine-selective targeting and anticancer effects of SapC-DOPS nanovesicles on brain tumors.Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma.The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma.Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway.Reirradiation as part of a salvage treatment approach for progressive non-pontine pediatric high-grade gliomas: preliminary experiences from the German HIT-HGG study group.The future of high-grade glioma: Where we are and where are we going.Transposon mediated integration of plasmid DNA into the subventricular zone of neonatal mice to generate novel models of glioblastoma.The management of lomustine overdose in malignant glioma patients.Effective long-term treatment with bevacizumab for relapsed glioblastoma: case report and review of the literatureRe-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model.Biopsy vs. extensive resection for first recurrence of glioblastoma: is a prospective clinical trial warranted?Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients.Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic dietLaser Ablation of Recurrent Malignant Gliomas: Current Status and Future Perspective.Single-cell sequencing maps gene expression to mutational phylogenies in PDGF- and EGF-driven gliomasMir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact.Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas.
P2860
Q26745942-128DA4CB-E4B7-454C-8759-8FDF9286E3F8Q26746622-2D984388-79FF-41DA-A92D-6D195CBF4FAEQ26795560-315F17DB-9A9B-41F7-A495-E8414A14F366Q26801351-A4431A59-E883-46CD-BAE3-48553A7EF655Q26995506-C09A8567-F9A8-41DB-A792-4F608810241FQ27021570-F31AC138-19E5-49D5-84A5-5D10E1B75A9DQ27853219-08DAE1EC-5F91-4F6C-862A-DEBD8F1F7CE9Q28067135-4F590C1A-C351-423A-9A27-433D4C169CB7Q28539628-2A5E5A3F-3F21-4EE5-902D-A3D71B18B9A6Q28546923-90A0818C-2EE9-4267-A181-274DE3569BE2Q29248396-ABCDA9A0-AC10-4094-9B53-6B656DFD5D13Q30422124-DF01623D-F5DB-49D2-9D78-B464001B5FE0Q30679553-B8DB73E2-B01E-42F0-81F3-9A0DEDB36325Q30737224-367E9E6D-2C08-47DA-A48E-6A3208B79453Q30860126-3057AF58-A59E-49B1-8468-F2BCC3FDAC9BQ30891381-F8C54A98-8887-4D8A-BC6C-48AF074F5EAAQ31033595-8DA3745E-1BF7-4BA3-B347-BD3148F645D2Q31113520-CB0D9351-1473-43BE-9978-EA3A2C4A230BQ33436470-E34DA984-CCFF-4D56-A49D-F855538095F6Q33586021-AAA6E74E-BD87-47D7-B080-71E6F35978A0Q33671783-16ABDDBF-937A-4969-8E13-A11DBE203C27Q33734645-37F88929-2511-484F-9DB3-3C7A903ED34AQ34334516-1AAD52D3-3C5F-4EC6-9852-A248CA315EE0Q34417525-F9BBD4AA-4C77-4050-B8DF-598C2A36B45EQ34468816-44B8D5F8-F8F3-4BC6-A9C3-05B6A3D65B4BQ34718233-1F18DB26-E3D8-4F6D-AEE2-93EC740DC1B8Q34812560-8F06B254-382A-4285-B5C5-15CA07A1185DQ35114090-021BB1BB-96CD-409C-80BA-9D5796917E8BQ35162299-2166FE81-AA60-4383-ADD3-7F2B81783C75Q35206271-5CD97368-F079-47CC-87E4-1B5559E8C0ABQ35580650-E0513E12-C67E-48C0-A445-6C658EC7F401Q35662578-FF26A98E-429A-48EE-B409-1ED2925D2D72Q35765099-0471208C-CAD3-4E21-9C0B-073FCEC2FDD8Q35788884-303953D6-6AA7-44A4-B660-143BAE401C9EQ35823287-074CFAF0-5475-4A76-B117-B833D02C80BEQ36017728-39321553-E244-4448-8230-CF8262406779Q36196954-75D2F384-AFC1-417B-AA48-0AE07755C507Q36204396-F150F140-6E0D-4E05-86AC-56A3FF3D7B46Q36272539-CB30BAC4-7F4F-4CCA-BDDD-7EE1F2622F5DQ36349882-FB559314-0196-4AD5-BD37-97D76FCDBAB8
P2860
Standards of care for treatment of recurrent glioblastoma--are we there yet?
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Standards of care for treatment of recurrent glioblastoma--are we there yet?
@ast
Standards of care for treatment of recurrent glioblastoma--are we there yet?
@en
type
label
Standards of care for treatment of recurrent glioblastoma--are we there yet?
@ast
Standards of care for treatment of recurrent glioblastoma--are we there yet?
@en
prefLabel
Standards of care for treatment of recurrent glioblastoma--are we there yet?
@ast
Standards of care for treatment of recurrent glioblastoma--are we there yet?
@en
P2860
P356
P1433
P1476
Standards of care for treatment of recurrent glioblastoma--are we there yet?
@en
P2093
James R Perry
Timothy Cloughesy
P2860
P356
10.1093/NEUONC/NOS273
P577
2012-11-07T00:00:00Z